Joel Randolph Hecht, MD of UCLA Health discusses phase II-III trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content